The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 360:2134-2136 May 14, 2009 Number 20
NextNext

Chemotherapy and Immunotherapy in Metastatic Colorectal Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Tol, J.
-PubMed Citation
To the Editor: Tol et al. (Feb. 5 issue)1 report that the addition of cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab reduced progression-free survival among patients with metastatic colorectal cancer, regardless of the KRAS status of the tumor. Similar results with panitumumab have been reported by Hecht et al.2

These results could be related to a reduced concentration of the main cytotoxic drug, oxaliplatin, caused by an artificially high level of plasma protein due to enormous doses of not one but two monoclonal antibodies.

In the blood, 6 hours after administration, 80 to 90% of oxaliplatin will become . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.